Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.5565 USD
−86.88 M USD
14.92 M USD
21.74 M
About Carisma Therapeutics, Inc.
Sector
Industry
CEO
Steven Kelly
Website
Headquarters
Philadelphia
Founded
2016
FIGI
BBG001J2N453
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CARM is 0.8584 USD — it has increased by 1.25% in the past 24 hours. Watch Carisma Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Carisma Therapeutics, Inc. stocks are traded under the ticker CARM.
CARM stock has fallen by −8.68% compared to the previous week, the month change is a −14.16% fall, over the last year Carisma Therapeutics, Inc. has showed a −65.25% decrease.
We've gathered analysts' opinions on Carisma Therapeutics, Inc. future price: according to them, CARM price has a max estimate of 24.00 USD and a min estimate of 4.00 USD. Watch CARM chart and read a more detailed Carisma Therapeutics, Inc. stock forecast: see what analysts think of Carisma Therapeutics, Inc. and suggest that you do with its stocks.
CARM reached its all-time high on Feb 26, 2014 with the price of 386.6520 USD, and its all-time low was 0.8000 USD and was reached on Aug 7, 2024. View more price dynamics on CARM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CARM stock is 1.79% volatile and has beta coefficient of 1.73. Track Carisma Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Carisma Therapeutics, Inc. there?
Today Carisma Therapeutics, Inc. has the market capitalization of 35.40 M, it has decreased by −4.01% over the last week.
Yes, you can track Carisma Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Carisma Therapeutics, Inc. is going to release the next earnings report on Apr 8, 2025. Keep track of upcoming events with our Earnings Calendar.
CARM earnings for the last quarter are −0.31 USD per share, whereas the estimation was −0.32 USD resulting in a 1.59% surprise. The estimated earnings for the next quarter are −0.17 USD per share. See more details about Carisma Therapeutics, Inc. earnings.
Carisma Therapeutics, Inc. revenue for the last quarter amounts to 3.38 M USD, despite the estimated figure of 5.47 M USD. In the next quarter, revenue is expected to reach 5.46 M USD.
CARM net income for the last quarter is −12.70 M USD, while the quarter before that showed −11.16 M USD of net income which accounts for −13.80% change. Track more Carisma Therapeutics, Inc. financial stats to get the full picture.
As of Nov 22, 2024, the company has 107.00 employees. See our rating of the largest employees — is Carisma Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Carisma Therapeutics, Inc. EBITDA is −62.01 M USD, and current EBITDA margin is −539.35%. See more stats in Carisma Therapeutics, Inc. financial statements.
Like other stocks, CARM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Carisma Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Carisma Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Carisma Therapeutics, Inc. stock shows the sell signal. See more of Carisma Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.